Tirzepatide Linked to 56% Lower Mortality Risk in 42,300 Patients with Sleep Apnea and Obesity | Research

The takeaway

In a large real-world study of 42,300 matched patients, tirzepatide was associated with 56% lower all-cause mortality, 27% fewer cardiovascular events, and 57% fewer kidney complications in people with obstructive sleep apnea and obesity.

56% lower all-cause mortality
Tirzepatide users had dramatically lower mortality (HR 0.443) compared to matched patients receiving lifestyle interventions alone, in a study of 42,300 people with sleep apnea and obesity.

What the researchers found

After propensity score matching of 42,300 patients (21,150 per group), tirzepatide was associated with significantly reduced risks of: all-cause mortality (HR 0.443, 95% CI: 0.336-0.583, representing a 56% risk reduction), major adverse cardiovascular events (HR 0.731, 95% CI: 0.622-0.859, a 27% risk reduction), and major adverse kidney events (HR 0.427, 95% CI: 0.343-0.530, a 57% risk reduction). These associations were consistent across subgroups stratified by age (except 18-39 years), sex, BMI, and CPAP use. Sensitivity analyses confirmed robustness.

Why it matters

OSA affects an estimated 1 billion people worldwide and is strongly linked to cardiovascular and kidney disease. Current treatment (CPAP) addresses the apnea itself but doesn't tackle the underlying obesity driving the condition. This study provides real-world evidence that tirzepatide may improve hard clinical outcomes — death, heart events, and kidney failure — beyond just weight loss and apnea scores.

How the study worked

Retrospective cohort study using the TriNetX Global Collaborative Network, a federated electronic health records database. Included adults with OSA and obesity between January 2022 and November 2024. Patients prescribed tirzepatide were compared to those receiving lifestyle interventions. Propensity score matching balanced covariates between groups. Primary outcome was all-cause mortality; secondary outcomes included major adverse cardiovascular events (MACEs) and major adverse kidney events (MAKEs). Subgroup and sensitivity analyses were performed.

What this study cannot tell us

This is an observational retrospective study, not a randomized trial — causation cannot be definitively established. Propensity score matching reduces but doesn't eliminate confounding. The TriNetX database may have coding inaccuracies and missing data. The control group receiving 'lifestyle interventions' is heterogeneous. The follow-up period (up to ~3 years) may be too short to capture long-term outcomes. The 18-39 age subgroup showed no benefit, possibly due to lower baseline event rates.

How to read the evidence

This is a large retrospective cohort study with propensity score matching using real-world electronic health records. While the sample size is impressive and results are robust across subgroups, the observational design cannot establish causation as definitively as a randomized trial. Residual confounding is possible.

When this study was published

Published in 2025 in CHEST, this is among the first large real-world studies examining tirzepatide's impact on hard clinical outcomes in OSA patients, complementing recent RCT data on apnea severity.

The bigger picture

GLP-1-based therapies are rapidly expanding beyond diabetes and weight loss into treating the full spectrum of obesity-related conditions. This study adds OSA to the growing list of conditions where tirzepatide shows cardiovascular and renal benefits. Combined with recent RCTs showing tirzepatide reduces sleep apnea severity, the evidence is building for a paradigm shift in how OSA is managed — treating the metabolic root cause rather than just the airway obstruction.

Questions still open

Will randomized controlled trials confirm these dramatic mortality and cardiovascular benefits in OSA patients?
Is the benefit driven primarily by weight loss, or does tirzepatide have independent cardiovascular and renal protective effects?
Why did the youngest age group (18-39) not show benefit — is this a power issue or a biological difference?

Common questions

Can tirzepatide help with sleep apnea?

This large real-world study found that tirzepatide use in people with OSA and obesity was associated with significantly lower risks of death, heart events, and kidney problems compared to lifestyle changes alone. Combined with clinical trial data showing tirzepatide reduces sleep apnea severity, the evidence suggests it may be a valuable treatment option for this population.

How much did tirzepatide reduce health risks in people with sleep apnea?

In this study of 42,300 matched patients, tirzepatide was associated with a 56% lower risk of death, 27% fewer cardiovascular events, and 57% fewer kidney complications. These benefits were seen across most age groups, both sexes, and regardless of whether patients were also using CPAP.

Read the original research

Clinical Impact of Tirzepatide on Patients With OSA and Obesity.

Chest, 168(3), 785-796

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Jheng-Yan; Chen, Chia-Chen; Ling Tu, Wan; Hsu, Wan-Hsuan; Liu, Ting-Hui; Tsai, Ya-Wen; Huang, Po-Yu; Chuang, Min-Hsiang; Hung, Kuo-Chuan; Yu, Tsung; Lai, Chih-Cheng. (2025). Clinical Impact of Tirzepatide on Patients With OSA and Obesity.. Chest, 168(3), 785-796. https://doi.org/10.1016/j.chest.2025.03.030